Edition:
United Kingdom

Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

2.78USD
21 Aug 2019
Change (% chg)

$0.01 (+0.36%)
Prev Close
$2.77
Open
$2.81
Day's High
$2.86
Day's Low
$2.68
Volume
324,904
Avg. Vol
354,115
52-wk High
$24.45
52-wk Low
$2.38

Latest Key Developments (Source: Significant Developments)

Amneal Pharmaceuticals Q2 Adjusted Earnings Per Share $0.09
Monday, 5 Aug 2019 

Amneal Pharmaceuticals Inc ::AMNEAL REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 REVENUE $405 MILLION VERSUS REFINITIV IBES ESTIMATE OF $428.6 MILLION.Q2 ADJUSTED EARNINGS PER SHARE $0.09.Q2 GAAP LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE ESTIMATE $0.14 -- REFINITIV IBES DATA.REAFFIRMS FULL YEAR 2019 EBITDA GUIDANCE.SEES FY 2019 ADJUSTED DILUTED EPS $0.52 - $0.62.SEES FY 2019 CAPITAL EXPENDITURES $65 MILLION - $85 MILLION.FY2019 EARNINGS PER SHARE VIEW $0.61 -- REFINITIV IBES DATA.  Full Article

Amneal Pharmaceuticals Co-Founders Chirag Patel And Chintu Patel Return As Co-Chief Executive Officers
Monday, 5 Aug 2019 

Amneal Pharmaceuticals Inc ::AMNEAL PHARMACEUTICALS CO-FOUNDERS CHIRAG PATEL AND CHINTU PATEL RETURN AS CO-CHIEF EXECUTIVE OFFICERS.AMNEAL PHARMACEUTICALS INC - PAUL MEISTER ELECTED CHAIRMAN OF BOARD.AMNEAL PHARMACEUTICALS INC - PAUL BISARO AND ROB STEWART HAVE RESIGNED AS EXECUTIVE CHAIRMAN, AND PRESIDENT AND CHIEF EXECUTIVE OFFICER.AMNEAL PHARMACEUTICALS - BISARO, STEWART HAVE STEPPED DOWN FROM BOARD.AMNEAL PHARMACEUTICALS - STEWART WILL SERVE AS AN ADVISOR TO CO THROUGH TRANSITION PERIOD.AMNEAL PHARMACEUTICALS - CHIRAG PATEL & CHINTU PATEL RESIGNED AS CO-CHAIRMEN OF BOARD, WILL REMAIN ON BOARD AS DIRECTORS.AMNEAL PHARMACEUTICALS - ROBERT BURR, JANET VERGIS AND DHARMENDRA RAMA HAVE RESIGNED AS INDEPENDENT DIRECTORS.AMNEAL PHARMACEUTICALS - RETAINED KORN FERRY TO ASSIST IN IDENTIFYING INDEPENDENT CANDIDATES FOR VACATED BOARD SEATS.  Full Article

Amneal Pharmaceuticals Says Expect To Reduce Headcount By About 550 By End Of 2020
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL PHARMACEUTICALS INC - EXPECT TO REDUCE HEADCOUNT BY APPROXIMATELY 550 BY END OF 2020.AMNEAL PHARMACEUTICALS INC - TO CLOSE MANUFACTURING FACILITY LOCATED IN HAUPPAUGE, NY AND PACKAGING FACILITY LOCATED IN EAST HANOVER, NEW JERSEY.AMNEAL PHARMACEUTICALS - DUE TO RESTRUCTURING, ESTIMATE A PRE-TAX RESTRUCTURING CHARGE OF ABOUT $10 TO $12 MILLION RELATED TO SEVERANCE BENEFITS.  Full Article

Amneal Pharmaceuticals Reduces FY 2019 Adjusted EBITDA Guidance
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL PHARMACEUTICALS ANNOUNCES RESTRUCTURING AND COSTS SAVINGS PLAN TO IMPROVE OPERATIONS AND POSITION THE COMPANY FOR FUTURE GROWTH.AMNEAL PHARMACEUTICALS ANNOUNCES RESTRUCTURING AND COSTS SAVINGS PLAN TO IMPROVE OPERATIONS AND POSITION THE COMPANY FOR FUTURE GROWTH.AMNEAL PHARMACEUTICALS INC - REDUCES FULL YEAR 2019 ADJUSTED EBITDA GUIDANCE.AMNEAL PHARMACEUTICALS INC - RESTRUCTURING PLAN EXPECTED TO REDUCE COSTS BY APPROXIMATELY $50 MILLION ANNUALLY.AMNEAL PHARMACEUTICALS INC - RESTRUCTURING PLAN IS EXPECTED TO REDUCE AMNEAL'S TOTAL ANNUAL COST BASE BY APPROXIMATELY $50.0 MILLION.AMNEAL PHARMACEUTICALS INC - CURRENTLY EXPECTS ADJUSTED EBITDA FOR 2019 TO NOW BE IN RANGE OF $425 MILLION TO $475 MILLION.AMNEAL PHARMACEUTICALS INC - MAJORITY OF RESTRUCTURING MILESTONES ARE EXPECTED TO BE ACHIEVED DURING 2020.AMNEAL PHARMACEUTICALS-MAJORITY OF RESTRUCTURING MILESTONES EXPECTED TO BE ACHIEVED DURING 2020, WITH FULL BENEFIT OF ACTIONS BEING REALIZED IN 2021, BEYOND.AMNEAL PHARMACEUTICALS INC - FULL BENEFIT OF RESTRUCTURING ACTIONS BEING REALIZED IN 2021 AND BEYOND.  Full Article

Amneal Q1 Adjusted Earnings Per Share $0.14
Thursday, 9 May 2019 

May 9 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 REVENUE $446 MILLION VERSUS REFINITIV IBES ESTIMATE OF $438.8 MILLION.Q1 ADJUSTED EARNINGS PER SHARE $0.14.Q1 GAAP LOSS PER SHARE $0.37.Q1 EARNINGS PER SHARE ESTIMATE $0.18 -- REFINITIV IBES DATA.REAFFIRMING FULL YEAR 2019 FINANCIAL GUIDANCE.Q1 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $438.8 MILLION -- REFINITIV IBES DATA.  Full Article

Amneal Pharmaceuticals Q4 Adjusted Earnings Per Share $0.33
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 REVENUE $498 MILLION VERSUS REFINITIV IBES ESTIMATE OF $481.1 MILLION.Q4 ADJUSTED EARNINGS PER SHARE $0.33.Q4 GAAP LOSS PER SHARE $0.07.Q4 EARNINGS PER SHARE ESTIMATE $0.27 -- REFINITIV IBES DATA.TARGETING UP TO 50 NEW GENERIC PRODUCT LAUNCHES IN 2019.PROVIDES 2019 FINANCIAL OUTLOOK.SEES 2019 ADJUSTED EBITDA $600 MILLION - $650 MILLION.SEES 2019 ADJUSTED DILUTED EPS $0.94 - $1.04.SEES 2019 CAPITAL EXPENDITURES APPROXIMATELY $100 MILLION.FY2019 EARNINGS PER SHARE VIEW $1.22 -- REFINITIV IBES DATA.CONTINUE TO EXPECT TO DELIVER AT LEAST $200 MILLION IN MERGER COST SYNERGIES BY THE END OF 2020.  Full Article

Amneal Pharmaceuticals Wins Tentative FDA Approval For Estradiol
Monday, 11 Feb 2019 

Feb 11 (Reuters) - FDA Website::AMNEAL PHARMACEUTICALS WINS TENTATIVE FDA APPROVAL FOR ITS DRUG ESTRADIOL - FDA WEBSITE.  Full Article

Amneal Names Todd Branning As Chief Financial Officer
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL NAMES ACCOMPLISHED FINANCE EXECUTIVE TODD P. BRANNING AS CHIEF FINANCIAL OFFICER.AMNEAL PHARMACEUTICALS INC - BRANNING SUCCEEDS BRYAN REASONS, WHO WILL REMAIN WITH COMPANY THROUGH END OF FEBRUARY 2019.  Full Article

Amneal Gets FDA Approval For Generic Version Of Exelon Patch
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES APPROVAL OF RIVASTIGMINE TRANSDERMAL SYSTEM.AMNEAL PHARMACEUTICALS INC - IS PLANNING TO COMMERCIALIZE ITS RIVASTIGMINE TRANSDERMAL SYSTEM SHORTLY..AMNEAL PHARMACEUTICALS - RECEIVED FDA APPROVAL FOR GENERIC VERSION OF EXELON PATCH (RIVASTIGMINE TRANSDERMAL SYSTEM).  Full Article

Amneal Pharmaceuticals Q3 Adjusted Earnings Per Share $0.28
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES SOLID THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 GAAP EARNINGS PER SHARE $0.05.Q3 EARNINGS PER SHARE VIEW $0.27 -- THOMSON REUTERS I/B/E/S.Q3 ADJUSTED EARNINGS PER SHARE $0.28.Q3 REVENUE $476.5 MILLION VERSUS I/B/E/S VIEW $486 MILLION.COMPANY TIGHTENS EXISTING 2018 FINANCIAL GUIDANCE.COMPANY TIGHTENS EXISTING 2018 FINANCIAL GUIDANCE.ON TRACK TO ACHIEVE MORE THAN $200 MILLION IN COST SYNERGIES.INTEGRATION OF AMNEAL AND IMPAX NEARING COMPLETION.POTENTIAL OPPORTUNITY TO LAUNCH UP TO 47 GENERIC PRODUCTS IN 2018 INCLUDING 8 LAST TWO MONTHS OF 2018.SEES FY 2018 ADJUSTED EPS OF $0.90 TO $0.92.SEES FY CAPEX ABOUT $90 MILLION.FY2018 EARNINGS PER SHARE VIEW $0.96 -- THOMSON REUTERS I/B/E/S.AMNEAL - TIGHTENED RANGE OF FY ADJUSTED EPS GUIDANCE DUE TO GENERIC COMPETITION, WHICH OCCURRED LATE IN Q3.  Full Article

RPT-GRAPHIC-Mylan stock boost follows long share struggles for company, generics industry

NEW YORK, July 29 Shares of Mylan NV surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug industry since 2015.